Kidney & Blood Pressure Research · 2007 · 29 citations · 27 references
MedicineNephrologyPharmacologyRenal PathologyRenal PathophysiologyRenal PharmacotherapyChronic Kidney DiseaseRenal DiseaseRenal HemodynamicsRenal PharmacologyUrinary ExcretionBlood PressureGuanylyl Cyclase IsoformsGuanylyl Cyclase RegulationKidney PathologyKidney PhysiologyRenoprotective EffectsRenoprotective TherapiesSoluble Guanylate Cyclase Stimulators
Nitric oxide formation is impaired in chronic renal failure. The renoprotective effects of a nonhypotensive dose of HMR1766, a direct activator of the heme enzyme soluble guanylyl cyclase was studied in comparison to an ACE-i in the remnant kidney model. Male Sprague-Dawley rats were subtotally nephrectomized (SNX) or sham operated (sham) and left untreated or started on treatment with HMR1766 or ACE-i in non-hypotensive doses. BP, albumin excretion and parameters of renal damage were analyzed. After a 12-week study, urinary albumin excretion was significantly higher in untreated SNX than in sham; this increase was prevented by ACE-i and ameliorated by HMR1766. Relative kidney and left ventricular weight were significantly higher in untreated SNX compared to sham; these changes were completely prevented by HMR1766. In untreated SNX, glomerulosclerosis (1.02 +/- 0.13) was significantly higher than in sham (0.12 +/- 0.04), SNX+HMR1766 (0.27 +/- 0.04) and SNX+ACE-i (0.46 +/- 0.06). Tubulointerstitial changes went in parallel. Increased glomerular cell number after SNX (71.5 +/- 14 vs. 60 +/- 7.3 in sham) was prevented by HMR1766 (55.7 +/- 7.3), but not by ACE-i (66.6 +/- 9). The results document beneficial BP-independent HMR1766 effects on kidney structure and urinary albumin excretion in a noninflammatory model of renal failure and may argue for a novel therapeutic principle.
27
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
A. Leone, S. Moncada, Patrick Vallance et al. · The Lancet · 1992 · 2.1K citations
Medicine, Nephrology, Pharmacology +11